Journal article
P11.14.A STEREOTACTIC RADIOSURGERY FOR OVARIAN CANCER BRAIN METASTASES: AN INTERNATIONAL RADIOSURGERY RESEARCH FOUNDATION RETROSPECTIVE STUDY
Neuro-oncology (Charlottesville, Va.), v 27(Supplement_3), pp iii106-iii106
03 Oct 2025
Abstract
Abstract
BACKGROUND
Ovarian cancer rarely metastasises to the brain, thus studies reporting the outcomes of affected patients are lacking. Stereotactic radiosurgery (SRS) is now the mainstay of management for patients with brain metastases (BM) from most primary sites, but little evidence of its efficacy in ovarian cancer is available. The current study was undertaken to provide guidance for SRS management using pooled data from multiple institutions.
MATERIAL AND METHODS
Centers participating in the IRRF (International Radiosurgery Research Foundation) were asked to provide outcome data for patients who had SRS for ovarian cancer brain metastases between 2020 and 2024 and at least one clinical and imaging follow-up after the procedure. Primary endpoints included survival from SRS, local tumor response according to RANO-BM criteria and occurrence of adverse radiation effects (ARE). Cox regression analyses were performed to identify variables impact each endpoint.
RESULTS
128 patients had SRS for a total of 532 BM treated. Epithelial histology was the most common (91%). Median age at SRS was 62 years (IQR 56-70). Median KPS was 80% (IQR 80-90%) and 71.9% of patients had neurological symptoms at presentation. Other active systemic metastases were present in 41.4%. The median number of treated BM was 2 (IQR1-3) and the median cumulative treatment volume was 6 cc (IQR 2-12.9). The median margin dose was 18 Gy (IQR 16-20). At last follow-up, 19.5% of patients were still alive. The median overall survival (OS) after SRS was 27 months, and 6-, 12- and 24-month OS was 83.8%, 74.2% and 52.2%, respectively. Multivariate analyses revealed that increasing age at SRS (HR 1.02, p=0.05), active systemic metastases (HR 2, p=0.005) and increasing number of brain metastases (HR 1.05, p=0.04) were associated with worse survival, while repeating SRS (HR 0.4, p=0.002) led to improved survival. Local failure occurred in 12.8% of treated BM. Actuarial progression-free survival (PFS) at 6, 12 and 24 months was 92.3%, 86.6% and 70.3%, respectively. Only prior WBRT (HR 4.36, p=0.03) led to worse local control on multivariate analyses. New remote BM appeared in 49.5% of patients and 14.5% suffered from leptomeningeal dissemination. ARE were seen in 12.1% of BM but were symptomatic in only 3.2%. On multivariate analyses, prior SRS (HR 3.13, p=0.002) was associated with increased risk of ARE.
CONCLUSION
Ovarian cancer brain metastases can be safely and effectively managed with SRS as the primary treatment modality in most patients.
Metrics
1 Record Views
Details
- Title
- P11.14.A STEREOTACTIC RADIOSURGERY FOR OVARIAN CANCER BRAIN METASTASES: AN INTERNATIONAL RADIOSURGERY RESEARCH FOUNDATION RETROSPECTIVE STUDY
- Creators
- D Mathieu - Université de SherbrookeM Billau - Université de SherbrookeA Hamel - Université de SherbrookeE Adam - Université de SherbrookeC Iorio-Morin - Université de SherbrookeR Liscak - Na Homolce HospitalJ May - Na Homolce HospitalA Niranjan - University of Pittsburgh Medical CenterZ Wei - University of Pittsburgh Medical CenterL LunsfordD Luy - University of Pittsburgh Medical CenterS Jose - University of Pittsburgh Medical CenterS Scanlon - University of Pittsburgh Medical CenterJ Silverman - NYU Langone HealthR Mullen - NYU Langone HealthK Bernstein - NYU Langone HealthD Kondziolka - NYU Langone HealthS Peker - Koç UniversityY Samanci - Koç UniversityA H DüzkalirS E Braunstein - University of California, San FranciscoC Phuong - University of California, San FranciscoJ Sheehan - University of VirginiaS Pikis - University of VirginiaJ Kosyakovsky - University of VirginiaR N Prasad - The Ohio State University Wexner Medical CenterJ D Palmer - The Ohio State University Wexner Medical CenterD Bailey - Pennsylvania State UniversityB E Zacharia - Pennsylvania State UniversityC Cifarelli - West Virginia UniversityD Cifarelli - West Virginia UniversityD Arteaga IcazaR E Wegner - Allegheny Health NetworkM J Shepard - Allegheny Health NetworkG N Bowden - University of AlbertaN Wandrey - University of Colorado DenverC G Rusthoven - University of Colorado DenverE B Hintz - Hofstra UniversityM Schulder - Hofstra UniversityA Goenka - Hofstra UniversityJ Peterson - WinnMed
- Publication Details
- Neuro-oncology (Charlottesville, Va.), v 27(Supplement_3), pp iii106-iii106
- Publisher
- Oxford University Press; CARY
- Number of pages
- 1
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Neurology
- Web of Science ID
- WOS:001587252100033
- Other Identifier
- 991022155295204721